Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients

Launched by AFFILIATED HOSPITAL OF NANTONG UNIVERSITY · Apr 25, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to treat advanced nasopharyngeal carcinoma (NPC), a type of throat cancer. Researchers are looking at whether a medication called HCQ, which can block a process in cancer cells, can help prevent the formation of certain dormant cancer cells that survive after chemotherapy and radiotherapy. These dormant cells, known as polyploid giant cancer cells (PGCCs), can lead to cancer coming back and spreading, which is a major concern for patients. By using HCQ before standard cancer treatments, the goal is to reduce the chances of these cells forming, ultimately aiming to improve survival rates for patients with NPC.

To participate in the trial, individuals need to have a confirmed diagnosis of NPC and should not have started any cancer treatments yet. They must also be willing to give informed consent to join the study. Importantly, this trial is currently recruiting participants of all genders and between certain ages, but those with cancer that has already spread to other parts of the body are not eligible. If you decide to join, you can expect to receive the HCQ treatment followed by the usual chemotherapy and radiotherapy, and the researchers will closely monitor your health and response to the treatment. This study represents a hopeful step towards improving outcomes for patients facing this challenging disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of NPC.
• • Have not received any cancer therapies
• • Must provide informed consent
• Exclusion Criteria:
• • With metastasis before the first treatment.